Dr. Frank J. Ayd Jr., a Baltimore psychiatrist who pioneered the field of psychopharmacology when he began treating schizophrenics with Thorazine in the early 1950s, died in his sleep Monday at Lorien Mays Chapel Health Care Center. He was 87.
At a time when the psychiatric establishment rejected the notion that mental illness was rooted in biology, Dr. Ayd championed the use of medications to adjust brain chemistry and, in so doing, relieve a patient's suffering.
"He was a biological psychiatrist, one of the important kinds of people who in spite of - and against - the establishment had the guts to stand up and really do things," said Dr. Thomas Ban, an emeritus professor of psychiatry at Vanderbilt University in Nashville, Tenn.
"Many people claim pioneering, but he really was. He entered the field when the whole thing started."
Dr. Philip G. Janicak, a Chicago psychiatrist and editor of International Drug Therapy Newsletter, said, "Dr. Ayd was one of the founding fathers of modern psychiatry. He changed the direction of psychiatry."
Dr. Janicak added: "He saw the potential value of medications to treat serious psychiatric disorders."
READ MORE @ BALTIMORE SUN
Showing posts with label Thorazine. Show all posts
Showing posts with label Thorazine. Show all posts
Thursday, March 20, 2008
Monday, June 11, 2007
Big Headache for Big Pharma
By - Will Hall co-founder of the Freedom Center, and a member of the Icarus Project.
READ MORE @ Adbusters
Monday, June 4, 2007
Antipsychotic Medicine Inspires Tuberculosis Drug
The antipsychotic medication chlorpromazine (Thorazine) can be used to treat tuberculosis, but it causes terrible side effects. Scientists at SRI International are using this knowledge as a starting point to develop a new tuberculosis drug. Their challenge is to find a chemical that kills Mycobacterium tuberculosis, the bacteria that causes tuberculosis, without causing restlessness and uncontrollable jitters that are brought on by the antipsychotic medication.
READ MORE @ Wired News
READ MORE @ Wired News
Subscribe to:
Posts (Atom)